Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Rhiannon Maudsley"'
Autor:
Lillian M. Smyth, Gerald Batist, Funda Meric-Bernstam, Peter Kabos, Iben Spanggaard, Ana Lluch, Komal Jhaveri, Andrea Varga, Andrea Wong, Alison M. Schram, Helen Ambrose, T. Hedley Carr, Elza C. de Bruin, Carolina Salinas-Souza, Andrew Foxley, Joana Hauser, Justin P. O. Lindemann, Rhiannon Maudsley, Robert McEwen, Michele Moschetta, Myria Nikolaou, Gaia Schiavon, Pedram Razavi, Udai Banerji, José Baselga, David M. Hyman, Sarat Chandarlapaty
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-7 (2021)
Abstract Five to ten percent of ER+ metastatic breast cancer (MBC) tumors harbor somatic PTEN mutations. Loss of function of this tumor-suppressor gene defines a highly aggressive, treatment-refractory disease for which new therapies are urgently nee
Externí odkaz:
https://doaj.org/article/97cb292e26054c75a968bad21fc37c9b
Autor:
Rhiannon Maudsley, Marta García-Fiñana
Publikováno v:
Image Analysis and Stereology, Vol 27, Iss 3, Pp 143-149 (2011)
Cavalieri sampling and point counting are frequently applied in combination with magnetic resonance (MR) imaging to estimate the volume of human brain compartments. Current practice involves arbitrarily choosing the number of sections and sampling in
Externí odkaz:
https://doaj.org/article/2f42a75a171447a5b683b8049f7203af
Autor:
David M. Hyman, José Baselga, Sarat Chandarlapaty, Barry S. Taylor, Maurizio Scaltriti, Udai Banerji, Gaia Schiavon, Vicky Rowlands, Martin Pass, Michele Moschetta, Robert McEwen, Rhiannon Maudsley, Justin P.O. Lindemann, Joana Hauser, Andrew Foxley, Elza C. de Bruin, Claire Corcoran, Des D. Cashell, Alan Barnicle, Jack Ashton, Helen J. Ambrose, Laura Biganzoli, Marie-Paule Sablin, Ingrid A. Mayer, Eva M. Ciruelos, Mafalda Oliveira, Kenji Tamura, Lillian M. Smyth
Supplementary Figure 1. Participant Flow Diagram
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4f3ddb7682626f66115790cb0108aba
https://doi.org/10.1158/1078-0432.22476300.v1
https://doi.org/10.1158/1078-0432.22476300.v1
Autor:
David M. Hyman, José Baselga, Sarat Chandarlapaty, Barry S. Taylor, Maurizio Scaltriti, Udai Banerji, Gaia Schiavon, Vicky Rowlands, Martin Pass, Michele Moschetta, Robert McEwen, Rhiannon Maudsley, Justin P.O. Lindemann, Joana Hauser, Andrew Foxley, Elza C. de Bruin, Claire Corcoran, Des D. Cashell, Alan Barnicle, Jack Ashton, Helen J. Ambrose, Laura Biganzoli, Marie-Paule Sablin, Ingrid A. Mayer, Eva M. Ciruelos, Mafalda Oliveira, Kenji Tamura, Lillian M. Smyth
Purpose:The activating mutation AKT1E17K occurs in approximately 7% of estrogen receptor–positive (ER+) metastatic breast cancer (MBC). We report, from a multipart, first-in-human, phase I study (NCT01226316), tolerability and activity of capivaser
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28c1b1cc28095071714876d36a725e47
https://doi.org/10.1158/1078-0432.c.6529365.v1
https://doi.org/10.1158/1078-0432.c.6529365.v1
Autor:
David M. Hyman, José Baselga, Sarat Chandarlapaty, Barry S. Taylor, Maurizio Scaltriti, Udai Banerji, Gaia Schiavon, Vicky Rowlands, Martin Pass, Michele Moschetta, Robert McEwen, Rhiannon Maudsley, Justin P.O. Lindemann, Joana Hauser, Andrew Foxley, Elza C. de Bruin, Claire Corcoran, Des D. Cashell, Alan Barnicle, Jack Ashton, Helen J. Ambrose, Laura Biganzoli, Marie-Paule Sablin, Ingrid A. Mayer, Eva M. Ciruelos, Mafalda Oliveira, Kenji Tamura, Lillian M. Smyth
Supplementary Figure 3. AKT1E17K Allele Frequency (AF) Distribution and Median AF for patients with available ctDNA NGS data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cc68c5e9ff3cae038afb89d5bd3f604
https://doi.org/10.1158/1078-0432.22476294
https://doi.org/10.1158/1078-0432.22476294
Autor:
David M. Hyman, José Baselga, Sarat Chandarlapaty, Barry S. Taylor, Maurizio Scaltriti, Udai Banerji, Gaia Schiavon, Vicky Rowlands, Martin Pass, Michele Moschetta, Robert McEwen, Rhiannon Maudsley, Justin P.O. Lindemann, Joana Hauser, Andrew Foxley, Elza C. de Bruin, Claire Corcoran, Des D. Cashell, Alan Barnicle, Jack Ashton, Helen J. Ambrose, Laura Biganzoli, Marie-Paule Sablin, Ingrid A. Mayer, Eva M. Ciruelos, Mafalda Oliveira, Kenji Tamura, Lillian M. Smyth
Supplementary tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55a0265a5795450271c65b9e3919ea10
https://doi.org/10.1158/1078-0432.22476291.v1
https://doi.org/10.1158/1078-0432.22476291.v1
Autor:
Jan H.M. Schellens, James Yates, Gaia Schiavon, Paul Rugman, Vicky Rowlands, Martin Pass, Rhiannon Maudsley, Justin P.O. Lindemann, Peter Lawrence, Andrew Foxley, Paul Elvin, Elza C. de Bruin, Barry R. Davies, Marie Cullberg, Claire Corcoran, S.Y. Amy Cheung, T. Hedley Carr, J. Carl Barrett, Helen Ambrose, Mathew Tall, Michelle D. Garrett, Peter Kabos, Shannon N. Westin, Benoit You, Philippe L. Bedard, Gerald Batist, J. Alejandro Pérez-Fidalgo, Emma J. Dean, Udai Banerji
Supplementary methods and results Supplementary Figure 1. Study 1 (NCT01226316) design Supplementary Figure 2. Dose escalation and DLTs in Part A, with MTDs of the continuous, 4/7, and 2/7 schedules being 320, 480, and 640 mg bid, respectively Supple
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee3d8d839a51fc0d03f0146dcc4e0fb1
https://doi.org/10.1158/1078-0432.22464402
https://doi.org/10.1158/1078-0432.22464402
Autor:
Jan H.M. Schellens, James Yates, Gaia Schiavon, Paul Rugman, Vicky Rowlands, Martin Pass, Rhiannon Maudsley, Justin P.O. Lindemann, Peter Lawrence, Andrew Foxley, Paul Elvin, Elza C. de Bruin, Barry R. Davies, Marie Cullberg, Claire Corcoran, S.Y. Amy Cheung, T. Hedley Carr, J. Carl Barrett, Helen Ambrose, Mathew Tall, Michelle D. Garrett, Peter Kabos, Shannon N. Westin, Benoit You, Philippe L. Bedard, Gerald Batist, J. Alejandro Pérez-Fidalgo, Emma J. Dean, Udai Banerji
Purpose: This phase I, open-label study (Study 1, D3610C00001; NCT01226316) was the first-in-human evaluation of oral AZD5363, a selective pan-AKT inhibitor, in patients with advanced solid malignancies. The objectives were to investigate the safety,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23540265cf512e0b58e65211bace9f79
https://doi.org/10.1158/1078-0432.c.6525705.v1
https://doi.org/10.1158/1078-0432.c.6525705.v1
Autor:
Nicholas Turner, Christos Vaklavas, Emiliano Calvo, Javier Garcia-Corbacho, Jason Incorvati, Manuel Ruiz Borrego, Chris Twelves, Anne Armstrong, Begoña Bermejo, Erika Hamilton, Mafalda Oliveira, Eva Ciruelos, Peter Kabos, Manish R Patel, Maria Borrell, Howard Burris, Bruno de Paula, Alejandro Falcon, Cristina Hernando, Irene Moreno, Ciara S. O’Brien, Elena Shagisultanova, Ivan Victoria Ruiz, Judy S. Wang, Mei Wei, Tim Brier, Danielle Carroll, Carmela Ciardullo, Lisa Gibbons, itziar irurzun-Arana, Tony Jack, bistra kirova, Teresa Klinowska, Justin Lindemann, Julie Maidment, Alastair Mathewson, Rhiannon Maudsley, Robert McEwen, Christopher Morrow, Andy Sykes, Richard D. Baird
Background: SERENA-1 (NCT03616587) is a Phase 1, multi-part, open-label study of camizestrant in women with ER+/HER2− advanced breast cancer. Parts A/B and C/D (escalation/expansion) examined camizestrant as monotherapy and in combination with palb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff3b0f1e0fcbdd82a029a528d47540d2
https://www.repository.cam.ac.uk/handle/1810/350214
https://www.repository.cam.ac.uk/handle/1810/350214
Autor:
Michele Moschetta, T. Hedley Carr, Robert McEwen, Alison M. Schram, Myria Nikolaou, Sarat Chandarlapaty, José Baselga, Gaia Schiavon, Funda Meric-Bernstam, Lillian M. Smyth, David M. Hyman, Andrea Li Ann Wong, Joana Hauser, Rhiannon Maudsley, Justin P.O. Lindemann, Iben Spanggaard, Andrew Foxley, Helen Ambrose, Pedram Razavi, Udai Banerji, Elza C. de Bruin, Carolina Salinas-Souza, Komal Jhaveri, Peter Kabos, Gerald Batist, Ana Lluch, Andrea Varga
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-7 (2021)
NPJ Breast Cancer
NPJ Breast Cancer
Five to ten percent of ER+ metastatic breast cancer (MBC) tumors harbor somatic PTEN mutations. Loss of function of this tumor-suppressor gene defines a highly aggressive, treatment-refractory disease for which new therapies are urgently needed. This